Nuvation Bio to Present at the Cantor Global Healthcare Conference
09 September 2024 - 10:00PM
Business Wire
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global
biopharmaceutical company tackling some of the greatest unmet needs
in oncology, today announced that David Hung, M.D., Founder,
President, and Chief Executive Officer of Nuvation Bio, will
present at the Cantor Global Healthcare Conference in New York, NY
on Thursday, September 19, 2024, at 9:45 a.m. E.T.
A live webcast of the presentation will be available on the
Nuvation Bio website at
https://investors.nuvationbio.com/investors/. An archived recording
will be available for 90 days following the event.
About Nuvation Bio
Nuvation Bio is a late clinical-stage, global biopharmaceutical
company tackling some of the greatest unmet needs in oncology by
developing differentiated and novel product candidates. Nuvation
Bio’s portfolio of development candidates includes taletrectinib
(ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET).
Nuvation Bio was founded in 2018 by biopharma industry veteran
David Hung, M.D., who previously founded Medivation, Inc., which
brought to patients one of the world’s leading prostate cancer
medicines. Nuvation Bio has offices in New York, San Francisco,
Boston, and Shanghai. For more information, please visit
www.nuvationbio.com and
https://www.linkedin.com/company/nuvationbio/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240909328377/en/
Nuvation Bio Investor Contact: ir@nuvationbio.com
Nuvation Bio Media Contact: media@nuvationbio.com
Panacea Acquisition (NYSE:NUVB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Panacea Acquisition (NYSE:NUVB)
Historical Stock Chart
From Dec 2023 to Dec 2024